EHA24: How I Treat Relapsed/Refractory Multiple Myeloma in Early Lines

Fredrik Schjesvold, Head of Oslo Myeloma Center, discusses his upcoming talk at EHA 2024 in Madrid about selecting second-line treatments for myeloma after the first relapse. He emphasizes considering overall survival and progression-free survival data, changing the mechanism of action, and the potential future impact of new drug combinations on treatment choices.